Data / Form D filings / Optimeos Life Sciences, Inc.
Optimeos Life Sciences, Inc.: Form D filings
Optimeos Life Sciences, Inc., a biotechnology company in Princeton, NJ, filed 5 Form D notices with the SEC between 2020 and 2026. The latest, on June 3, 2026, reports $1 million sold of a $2 million offering to 1 investor.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 174 NASSAU STREET, SUITE 334, Princeton, NJ, 08542
- Phone
- (609) 658-9839
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1819114
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Jun 3, 2026 | New notice | $2,000,000 | $1,000,000 | $1,000,000 | 1 | May 22, 2026 | sec.gov |
| Nov 26, 2024 | Amendment | $5,000,000 | $2,924,996 | $2,075,004 | 5 | Jun 26, 2023 | sec.gov |
| Jul 7, 2023 | New notice | $5,000,000 | $1,875,004 | $3,124,996 | 4 | Jun 26, 2023 | sec.gov |
| Jun 1, 2021 | New notice | $300,000 | $175,000 | $125,000 | 4 | May 17, 2021 | sec.gov |
| Aug 7, 2020 | New notice | $400,000 | $270,000 | $130,000 | 3 | Aug 6, 2020 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Shahram Hejazi | Executive Officer, Director | |
| Robert K Prud'homme | Director | |
| Jason Smith | Director | |
| Benjamin Doranz | Director |
Other biotechnology companies in New Jersey that filed recently
- Ensho Therapeutics, Inc. $7.3 million · Oct 15, 2026
- Xenon Ophthalmics Inc $3.3 million · Oct 6, 2026
- LISATA THERAPEUTICS, INC. $351.9 million · Oct 2, 2026
- Bullseye Biodevices, Inc. $1.3 million · Aug 10, 2026
- Hepion Pharmaceuticals, Inc. $3.1 million · Aug 5, 2026
Every Form D from the week of Jun 1, 2026 · All recent filings in New Jersey · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Optimeos Life Sciences, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.